Pipeline Overview
CoMentis is currently pursuing development of the following core product programs:| Product or Program | Pre-Clinical | Phase I |
Phase II | Phase III |
|---|---|---|---|---|
| Age-related macular degeneration | ||||
| ATG-3 (Topical Eye Drop Angiogenesis Inhibitor) |  |
 |
||
| CTS-21166 (Beta Secretase Inhibitor) |  |
|||
| Next Generation Beta Secretase Inhibitor | |
|||
| Cognition | ||||
| α7-nAChR Agonist |  |
|||